Algert Global LLC Makes New $108,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)

Algert Global LLC purchased a new stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 39,115 shares of the company’s stock, valued at approximately $108,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Harvest Investment Services LLC purchased a new stake in Inozyme Pharma during the fourth quarter valued at $31,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at about $38,000. Palumbo Wealth Management LLC grew its stake in shares of Inozyme Pharma by 52.3% during the 4th quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock valued at $64,000 after purchasing an additional 7,995 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Inozyme Pharma during the 4th quarter valued at about $68,000. Finally, XTX Topco Ltd bought a new position in shares of Inozyme Pharma in the 4th quarter worth approximately $88,000. 88.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on INZY. Piper Sandler decreased their price target on shares of Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a research note on Thursday, April 10th. Wedbush reiterated an “outperform” rating and set a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a research report on Monday, March 10th. Raymond James cut their price target on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Inozyme Pharma in a research report on Tuesday, April 8th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $14.63.

Inozyme Pharma Price Performance

Inozyme Pharma stock opened at $1.09 on Wednesday. Inozyme Pharma, Inc. has a 12-month low of $0.72 and a 12-month high of $6.24. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.93. The firm has a market capitalization of $70.37 million, a PE ratio of -0.70 and a beta of 1.35.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.